Gain Therapeutics, Inc. has announced significant advancements in its lead drug candidate, GT-02287, which is currently in a Phase 1b clinical trial for the treatment of Parkinson’s disease (PD), including cases with the common GBA1 mutation. GT-02287 is an orally administered, brain-penetrant allosteric enzyme modulator designed to restore the function of the lysosomal enzyme glucocerebrosidase (GCase), which is often impaired due to genetic mutations or age-related stressors. Preclinical studies have shown that GT-02287 not only restores GCase activity but also mitigates key pathological features of PD, such as α-synuclein aggregation, neuroinflammation, and neuronal death.

The significance of these findings lies in GT-02287’s potential to act as a disease-modifying therapy for Parkinson’s disease. In rodent models, the drug candidate demonstrated improvements in motor function and behavioral deficits, alongside reductions in biomarkers of neurodegeneration, such as plasma neurofilament light chain (NfL) levels. Initial results from the ongoing Phase 1b trial indicate favorable safety and tolerability profiles, as well as evidence of central nervous system target engagement and a reduction in glucosylsphingosine levels, a key metabolic marker.

The implications of Gain Therapeutics’ work with GT-02287 extend beyond immediate therapeutic applications. This research could shift current paradigms in neurodegenerative disease treatment by emphasizing the importance of allosteric modulation as a strategy to restore enzyme function. As the drug progresses through clinical trials, it may pave the way for accelerated timelines in drug development for other lysosomal storage disorders and neurodegenerative conditions, potentially influencing how future therapies are designed and implemented in clinical settings.

Source: globenewswire.com